Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

TB transmission and prevention news

Show

From To
Isoniazid alone prevents tuberculosis in people with advanced HIV, urine test may lower mortality

Using isoniazid alone to prevent the development of active tuberculosis (TB) in people with advanced HIV disease was equally effective and better tolerated than a common four-drug empirical

Published
25 March 2016
By
Liz Highleyman
Proactively treating HIV patients at risk for tuberculosis with multidrug TB therapy doesn’t save more lives

In what investigators say is a surprise finding, results of a new study appear to strongly affirm the effectiveness of prescribing the anti-tuberculosis drug isoniazid alone — in place of the standard four-drug regimen — to prevent TB and reduce death in people with advanced HIV/AIDS infections. Those with HIV and AIDS are highly susceptible to TB.

Published
21 March 2016
From
Johns Hopkins Medicine
Screen High-Risk Adults for Tuberculosis, Experts Say

Adults at greater risk for latent tuberculosis infection should be screened for the condition, the U.S. Preventive Services Task Force recommends.

Published
09 March 2016
From
U.S. News & World Report
South Africa’s XDR-TB epidemic is due to transmission rather than evolution of resistant strains

A study in KwaZulu-Natal, South Africa, evaluating the social networks as well as clinical and genotypic data from individuals with extensively drug resistant tuberculosis (XDR-TB) has concluded that

Published
04 March 2016
By
Theo Smart
Three-month isoniazid/pyrazinamide regimen prevents TB as well as 6-month isoniazid in people living with HIV

A daily three-month regimen of isoniazid and pyrazinamide is just as effective at preventing the development of active tuberculosis (TB) as a six-month course of isoniazid in

Published
22 October 2015
By
Keith Alcorn
Presumptive treatment of TB in advanced HIV no better than giving ART and isoniazid

Giving treatment for tuberculosis to all people with very advanced HIV disease at the time they start antiretroviral therapy, before a laboratory diagnosis of TB –

Published
21 July 2015
By
Keith Alcorn
Starting HIV treatment at CD4 count above 500 reduces the risk of serious illness and death by 44%, African Temprano trial shows

Starting HIV treatment at a CD4 cell count above 500 reduced the risk of serious illness including tuberculosis (TB), and death, by 44% when compared to starting

Published
26 February 2015
By
Keith Alcorn
XDR-TB in South Africa is largely spread person-to-person, not by failure of drug treatment

The vast majority of people with extensively drug-resistant tuberculosis (XDR-TB) diagnosed in the world’s most extensive outbreak have acquired their infection from another person, not as the

Published
26 February 2015
By
Keith Alcorn
European HIV response "falling behind" as Eastern European epidemic grows

HIV diagnoses have increased by 80% in the European region since 2004, and three quarters of new HIV diagnoses in the European region are occurring in Eastern

Published
05 December 2014
By
Keith Alcorn
Sanofi: FDA Approves Priftin Tablets To Treat Latent Tuberculosis Infection

French drug maker Sanofi announced Tuesday that Priftin (rifapentine) tablets for the treatment of latent tuberculosis infection has received approval from the U.S. Food and Drug Administration.

Published
02 December 2014
From
RTT News

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.